Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PRTG

Portage Biotech Inc

May 03 • 10:26AM ET

0.2511

Dollar change -0.0088
Percentage change -3.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.87	Insider Own	34.91%	Shs Outstand	17.61M	Perf Week	4.54%
Market Cap	3.35M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	0.00%	Shs Float	8.67M	Perf Month	-51.38%
Income	-144.90M	PEG	-	EPS next Q	-0.22	Inst Own	17.02%	Short Float	0.10%	Perf Quarter	-64.63%
Sales	0.00M	P/S	-	EPS this Y	58.09%	Inst Trans	-10.21%	Short Ratio	0.09	Perf Half Y	-86.85%
Book/sh	1.62	P/B	0.16	EPS next Y	76.10%	ROA	-110.92%	Short Interest	0.01M	Perf Year	-92.03%
Cash/sh	0.40	P/C	0.63	EPS next 5Y	-	ROE	-144.22%	52W Range	0.20 - 4.40	Perf YTD	-86.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-449.66%	52W High	-94.29%	Beta	100.01
Dividend TTM	-	Quick Ratio	2.78	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.61%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	2.78	EPS Y/Y TTM	-570.82%	Oper. Margin	0.00%	RSI (14)	36.26	Volatility	11.95% 26.62%
Employees	7	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-328.89%	Payout	-	Rel Volume	2.28	Prev Close	0.26
Sales Surprise	-	EPS Surprise	-596.30%	Sales Q/Q	-	Earnings	Feb 28 AMC	Avg Volume	97.85K	Price	0.25
SMA20	-23.86%	SMA50	-46.30%	SMA200	-83.18%	Trades		Volume	41,617	Change	-3.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$26
Mar-07-22	Initiated	H.C. Wainwright	Buy	$32
Sep-21-21	Initiated	Oppenheimer	Outperform	$30
Sep-02-21	Initiated	B. Riley Securities	Buy	$40
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight	$35

Apr-15-24 07:05AM	Immuno-oncology company Portage Biotech to evaluate strategic alternatives (Pharmaceutical Business Review) -25.27%
Apr-12-24 10:33AM	Portage Biotech previews possible closure as it halts programs, hunts for strategic options (FierceBiotech.com) -9.00%
08:01AM	Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives (GlobeNewswire)
Mar-26-24 08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire) +9.73%
Feb-28-24 05:10PM	Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update (GlobeNewswire)
08:00AM	Loading…
Jan-04-24 08:00AM	Portage Biotech Reports Business and Strategic Update (GlobeNewswire)
Nov-28-23 04:01PM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update (GlobeNewswire) +8.46%
Nov-06-23 08:01AM	Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-29-23 08:00AM	Portage Biotech Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -7.52%
Sep-20-23 08:00AM	Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors (GlobeNewswire) +26.81%
Aug-30-23 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update (GlobeNewswire) -13.36%
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +7.69%
Jun-26-23 08:00AM	Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors (GlobeNewswire)
Jun-05-23 08:00AM	Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Jun-01-23 08:00AM	Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference (GlobeNewswire) +5.17%
Apr-26-23 05:00PM	Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Portage Biotech to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.69%
Mar-01-23 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022 (GlobeNewswire)
Feb-27-23 04:05PM	Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer (GlobeNewswire) +6.94%
Feb-15-23 08:00AM	Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Nov-29-22 04:43PM	Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022 (GlobeNewswire)
Nov-10-22 09:00AM	Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-08-22 08:00AM	Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck (GlobeNewswire)
Sep-14-22 08:39AM	Portage Biotech Provides Research and Development Update (GlobeNewswire)
Sep-08-22 08:00AM	Portage Biotech to Present at Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-29-22 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022 (GlobeNewswire)
Aug-18-22 08:00AM	Portage Biotech Announces Leadership Updates (GlobeNewswire)
Aug-01-22 09:10AM	UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
09:00AM	Loading…
Jul-20-22 09:00AM	Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform (GlobeNewswire) +6.13%
Jul-06-22 04:05PM	Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway (GlobeNewswire)
Jun-06-22 08:00AM	Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study (GlobeNewswire) -8.47%
Apr-25-22 08:00AM	Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity (GlobeNewswire) +8.33%
Apr-13-22 10:00AM	Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting (GlobeNewswire) +8.95%
Mar-31-22 08:00AM	Portage Biotech Provides Update on Clinical-Stage and Development Programs (GlobeNewswire)
Mar-09-22 09:00AM	Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-24-22 05:43PM	Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year (GlobeNewswire) +13.79%
Feb-15-22 08:00AM	Portage Biotech Announces New Appointments to its Management Team and Board of Directors (GlobeNewswire) +11.90%
Jan-05-22 08:00AM	Portage Biotech Announces Participation in January 2022 Investor Conferences (GlobeNewswire)
Nov-23-21 08:00AM	Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year (GlobeNewswire)
Nov-22-21 04:53PM	Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire) -7.06%
Nov-15-21 08:00AM	Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics INT230-6 (PORT-1) at November Scientific Conferences (GlobeNewswire)
Nov-10-21 08:00AM	Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment (GlobeNewswire) -6.53%
Oct-26-21 10:13AM	2 Strong Buy Stocks Oppenheimer Predicts Will Surge at Least 50% (TipRanks)
Sep-10-21 08:00AM	Portage Biotech Announces Participation in September 2021 Investor Conferences (GlobeNewswire)
Aug-30-21 08:00AM	Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year (GlobeNewswire)
Aug-12-21 08:00AM	Portage Biotech Issues Letter to Shareholders (GlobeNewswire)
Aug-05-21 08:00AM	Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) +14.29%
Jul-28-21 08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021 (GlobeNewswire)
Jun-29-21 09:00AM	Portage Biotech Added to Russell 2000(R) Index (Newsfile) -5.21%
Jun-24-21 09:00AM	Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares (Newsfile) -25.43%
08:56AM	Thursdays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-23-21 04:10PM	Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares (Newsfile)
Jun-02-21 08:30AM	Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting (Newsfile)
Apr-16-21 09:00AM	Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange (Newsfile) -7.06%
Apr-08-21 09:00AM	Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors (Newsfile)
Mar-25-21 09:00AM	Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics (Newsfile)
Mar-04-21 08:00AM	Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd (Newsfile) -17.86%
Mar-02-21 08:00AM	Portage Announces Filing of Third Quarter Financial Statements (Newsfile) +5.98%

Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTG

Portage Biotech Inc

Upgrade your FINVIZ experience